核转录因子和明胶酶在鼻息肉中的表达及临床意义

Expression and clinic function of STAT3 and MMP-2 and 9 in nasal polyp tissue

目的观察核转录因子(p-STAT3)及明胶酶(MMPs)在鼻息肉组织中的表达情况,探讨两者在鼻息肉发病过程中的作用及相互关系,为鼻息肉的临床治疗提供帮助和新的思路。方法收集潍坊医学院附属医院耳鼻喉科2008年5月-2013年4月期间行鼻内镜手术的患者45例(鼻息肉组35例,下鼻甲黏膜组10例),采用常规病理和免疫组织化学方法检测p-STAT3和MMP-2、9在鼻息肉及下鼻甲组织中的表达情况。结果MMP-2、9在鼻息肉组和下鼻甲黏膜组的表达分别为68.6%(24/35)、20%(2/10);82.9%(29/35)、20%(2/10),鼻息肉组与下鼻甲黏膜组比较差异有统计学意义(P<0.05)。p-STAT3在鼻息肉及下鼻甲黏膜组的阳性表达率为71.4%(25/35)、0.0%,两者比较差异有统计学意义(P<0.05)。P-STAT3和MMP-2、9存在着正相关关系(r=0.278,r=0.312,P<0.05)。结论 p-STAT3和MMP-2、9在鼻息肉组织的高表达和正相关性说明两者在鼻息肉的发病过程中起着重要作用,可作为临床治疗鼻息肉病的检测指标之一。

【Objective】 To observe the expression and clinical role of p-STAT3 and MMP-2 and 9 in the tissue of nasal polyps and to investigate their relationship in the development of nasal polyps so as to provide help and new ideas for clinical treatment of nasal polyps. 【Methods】 The expressions of p-STAT3 and MMP-2 and 9 were detected in the tissue of nasal polyps and inferior turbinate by routine pathologic and immunohistochemical methods. A total of 45 patients received nasal endoscopic surgery in the Department of Otorhinolaryngology of the Affiliated Hospital of Weifang Medical University from May 2008 to April 2013（35 cases in nasal polyp group and 10 cases in the inferior turbinate mucosa group）. 【Results】 The expression rates of MMP-2 and MMP-9 were 68.6%（24/35） and 82.9%（29/35） in the nasal polyp group and 20%（2/10） and 20%（2/10） in the inferior turbinate mucosa group, respectively. There was obvious difference between both groups（P〈0.05）. The expression rate of p-STAT3 was 71.4%（25/35） and 0.0% in the nasal polyp group and the inferior turbinate mucosa group respectively, there was a statistical difference between both groups（P〈0.05）. There were positive correlations between p-STAT3 and both MMP-2 and 9（r = 0.278 and 0.312, P〈0.05）. 【Conclusions】 The high expressions of p-STAT3 and MMP-2 and 9 in nasal polyps and positive correlations illustrate they all play important roles in the pathogenesis of nasal polyps and can be used as markers of clinical treatment for nasal polyposis.